10/581164

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:

Dana Rae Benesh

For:

OPIOID RECEPTOR ANTAGONISTS

Docket No.:

X-16095

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

John C. Demeter

Attorney for Applicant(s) Registration No. 30,167

Phone: 317-276-3785

Eli Lilly and Company Patent Division P.O. Box 6288

Indianapolis, Indiana 46206-6288

April 11, 2006

Sheet 1 of 1

| FORM PTO | (modified) | Atty. Dock | Atty. Docket No. | | | Serial No. 581164 | | | |
|-----------------------|------------------|--|--------------------------------|--------------------------------|--------------------------------------|--|---|--|----|
| INFORMA | TION E | DISCLOSURE CITATION | | First Applicant | | | | | |
| IN AN API | NOI | Dana Rae | Dana Rae Benesh | | | | | | |
| | • | Filing Date | Filing Date | | | | | | |
| | | | | | | | | | |
| U.S. PAT | ENT | DOCUMENTS | | | | | | | |
| Examiner Initials* | Cite | Document Number | | Publication Date MM-DD-YYYY | | Name of Patentee or Applicant of Cited Document | | Pages, Columns, Lines, | |
| initiais. | No. ¹ | Number-Kind Code ² (if know | | | | | ited Document | or Relevant Pages or Relevant Figures Appear | |
| | AA | US 2005/182040 | August 18, 200 | | 15 | Sughrue Mion PLLC | | | |
| FOREIG | N PA | TENT DOCUMENT | S | · · · · · · | | | | | |
| Examiner Initials* | Cite | Foreign Patent Document | | | | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | т6 |
| Indais | No. 1 | Country Code ³ -Number ⁴⁻ Kind Code5 (if known) | Publication Date MM-DD-YYYY | | | | | | |
| | BA | JP 2004/002367 | January 8, 2004 | | Tanabe Seiyaku Co. | | | | |
| | BB | WO 2004/037800 | May 6, 2004 | | Glaxo Group Limited | | | - " | |
| | BC | WO 99/33806 | July 8, 1999 | | Ortho-McNeil Pharmaceutical | | | | |
| | BD | EP 1 072 592 | January 31, 2001 | | Pfizer Inc. | | | | |
| | BE | WO 01/74806 | October 11, 2001 | | Astrazeneca AB | | | | |
| | BF | WO 02/48122 | June 20, 2002 | | Ortho-McNeil Pharmaceutical | | | | |
| | BG | WO 01/46174 | June 28, 2001 | | Astrazeneca AB | | | | |
| | ВН | WO 03/029233 | April 10, 2003 | | Richter Gedeon Vegyeszeti Gyar RT | | | | |
| | Bl | WO 2004/026305 | April 1, 2004 | | Eli Lilly and Company | | | | |
| | ВЈ | WO 2004/080968 | September 23, 2004 | | Eli Lilly and Company | | | | |
| | BK | WO 2004/080996 | September 23, 2004 | | Eli Lilly and Company | | | | |
| NON PA | TENT | LITERATURE DO | | ENTS | Compan | <u> </u> | L | | 1 |
| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | | | | | | | |
| | CA | | | | | | | | |
| Examiner | | | | | Data Cons | ., ., . | | | |

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov on MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be ret to the Chief Information Officer. US. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.